Bangalore, April 26, 2007: Pharmaceutical and biotech companies from the West and Asia will convene in Shanghai, China this May 20–23, 2007 at the Impact China III: Pharmaceutical R&D Global Summit to discuss the current trends and challenges facing China’s fast-growing pharmaceutical sector.

 

China has quickly become the international destination of choice for the multinational pharmaceutical and biotech companies, who are looking at China to strengthen and expedite their drug discovery and development efforts.

 

Organized by ALM’s Strategic Research Institute, based in New York, this industry-leading event is designed to bring together pharma and biotech executives from around the world to gather strategic information and network amongst each other to facilitate new investment and foster new partnerships in China.

 

The event will feature over 65 presentations from companies including: Amgen, AstraZeneca, Bayer Schering Pharma, Boston Consulting Group, Bristol-Myers Squibb, Burrill & Co., Chipscreen Biosciences, Fidelity Investments, Goldman Sachs, Janssen China, Merck, Novartis, Novo Nordisk, Onyx Pharmaceuticals, Pfizer, RHEI Pharmaceuticals, and many more.

 

An international audience consisting of senior-level pharma and biotech executives from the business development, strategic planning, clinical development, global sourcing and R&D functions are expected to attend the event.